NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business Development of Oramed, will deliver a corporate presentation, including an [...]
NEW YORK, May 21, 2019 /PRNewswire/ -- ORMD-0801 reaches significant milestone on path to potentially be the first commercial oral insulin capsule for the treatment of Type 2 diabetes Close to 300 patients have now been enrolled. 70% of patients have already completed treatment in the [...]
NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. [...]
NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]
NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]
NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place [...]
NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for [...]
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of [...]
NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]
JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 [...]